Status:
COMPLETED
LSD-Perceptual-Choice-Study
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
University of Basel
University Psychiatric Clinics Basel
Conditions:
LSD Reaction
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of the study is to characterize the effects of low doses of LSD (d-lysergic acid diethylamide) on behavioral and neural indicators of feedback and feedforward signaling in perceptual decision-...
Detailed Description
The study team will subject healthy participants to multiple perceptual decision-making tasks after the administration of low doses of LSD (d-lysergic acid diethylamide) as a pharmacological challenge...
Eligibility Criteria
Inclusion
- Willingness to adhere to the study protocol and sign the consent form
- ≥ 18 and ≤ 65 years of age at Screening
- Body mass index 18-29
- Fluent understanding of German
- Normal or corrected-to-normal vision
- Willingness to not operate a traffic vehicle or heavy machinery 24 hours after substance administration
- Willingness to refrain from taking illicit psychoactive substances, including cannabis, for the duration of the study
- Willingness to not consume more than one alcoholic standard drink the night before the study sessions and not consume alcohol for 24 h after each study session
- Willingness to abstain from xanthine-based liquids from the evenings prior to the study sessions and during the sessions
- Willingness to use effective birth-control throughout the study duration
- Adequate task performance in the decision-making tasks during a practice session in the screening visit
Exclusion
- Recent (\<30 days) or current participation in another clinical trial
- Women that are pregnant, nursing, or planning to become pregnant during the study period
- Current use of contraindicated/psychoactive medications or illicit drugs
- Lifetime use of classical psychedelics more than 20 times, or any time within the previous two months
- Consumption of \>5 cigarettes per day or \>20 alcoholic standard drinks per week
- Severe chronic or acute medical condition
- Hypertension (\>140/90 mmHg) or hypotension (\<85mmHg systolic)
- Current or lifetime major mental health disorder
- Personal or family (first-degree) history of a primary psychotic disorder
Key Trial Info
Start Date :
February 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 25 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05976698
Start Date
February 26 2024
End Date
February 25 2025
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Psychiatric Clinics Basel
Basel, Switzerland, 4002